Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Symbicort SMART versus Seretide plus terbutaline in persistent asthma
2004-004905-11Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of budesonide, salmeterol + fluticasone and terbutaline in persistent asthma (2 arms), sponsored by AstraZeneca. Primary endpoint: Time to first severe asthma exacerbation. Started Sep 2005; status: completed.
02
Drugs
budesonidesalmeterol + fluticasoneterbutaline
03
Conditions
persistent asthma
Beyond the preview
Go deeper on 2004-004905-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004905-11.